Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Amortization - IntangiblesConsolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeInterest ExpensesNet Income towards Common StockholdersOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxRestructuring CostsRevenueSelling, General & AdministrativeShares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Collegium Pharmaceutical (COLL) Interest Expenses: 2016-2025

Historic Interest Expenses for Collegium Pharmaceutical (COLL) over the last 9 years, with Sep 2025 value amounting to $21.8 million.

  • Collegium Pharmaceutical's Interest Expenses rose 18.34% to $21.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was $85.7 million, marking a year-over-year increase of 21.35%. This contributed to the annual value of $74.0 million for FY2024, which is 11.24% down from last year.
  • As of Q3 2025, Collegium Pharmaceutical's Interest Expenses stood at $21.8 million, which was up 6.37% from $20.5 million recorded in Q2 2025.
  • In the past 5 years, Collegium Pharmaceutical's Interest Expenses registered a high of $22.7 million during Q4 2024, and its lowest value of $4.8 million during Q4 2021.
  • Moreover, its 3-year median value for Interest Expenses was $20.8 million (2023), whereas its average is $20.0 million.
  • Per our database at Business Quant, Collegium Pharmaceutical's Interest Expenses crashed by 38.52% in 2021 and then soared by 332.52% in 2022.
  • Collegium Pharmaceutical's Interest Expenses (Quarterly) stood at $4.8 million in 2021, then spiked by 332.52% to $20.6 million in 2022, then dropped by 6.29% to $19.3 million in 2023, then climbed by 17.49% to $22.7 million in 2024, then rose by 18.34% to $21.8 million in 2025.
  • Its Interest Expenses was $21.8 million in Q3 2025, compared to $20.5 million in Q2 2025 and $20.8 million in Q1 2025.